Wetterling Tilman, Schneider Barbara, Weber Bernhard
Klinik für Psychiatrie und Psychotherapie, J.-W. Goethe-Universität Frankfurt/Main.
Psychiatr Prax. 2007 Mar;34(2):76-80. doi: 10.1055/s-2006-940051. Epub 2006 Dec 7.
There is some evidence that the treatment with new ("atypical") antipsychotics is associated with a higher frequency of type 2-diabetes mellitus.
In this study the blood glucose levels of consecutively admitted inpatients with chronic schizophrenia were investigated.
The base blood glucose levels of 177 consecutively admitted chronic schizophrenic patients were evaluated.
After long-term treatment (mean duration: 17.8 +/- 8.7 years [range 5 - 44 years]) 24.3 % of the investigated patients showed elevated base blood glucose levels (> or = 126 mg/dl). The proportion of patients with elevated blood glucose levels among the schizophrenic patients treated with antipsychotics was significantly higher than the proportion of diabetics in the corresponding age groups in the general population. The comparison of different groups of antipsychotics revealed that those patients treated with conventional neuroleptics and non-dibenzodiazepine derivates (i. e. risperidone) had a lower risk of developing diabetes mellitus than those also receiving dibenzodiazepine derivates (like clozapine, olanzapine).
Our data showed that schizophrenic patients treated with antipsychotics 5 years or longer had elevated blood glucose levels more frequently than the general population.
有证据表明，使用新型（“非典型”）抗精神病药物进行治疗与2型糖尿病的较高发病率相关。
本研究对连续收治的慢性精神分裂症住院患者的血糖水平进行了调查。
对177例连续收治的慢性精神分裂症患者的基础血糖水平进行了评估。
经过长期治疗（平均病程：17.8±8.7年[范围5 - 44年]），24.3%的受调查患者基础血糖水平升高（≥126mg/dl）。在接受抗精神病药物治疗的精神分裂症患者中，血糖水平升高的患者比例显著高于普通人群中相应年龄组的糖尿病患者比例。对不同组抗精神病药物的比较显示，接受传统抗精神病药物和非二苯二氮䓬衍生物（即利培酮）治疗的患者患糖尿病的风险低于同时接受二苯二氮䓬衍生物（如氯氮平、奥氮平）治疗的患者。
我们的数据表明，接受抗精神病药物治疗5年或更长时间的精神分裂症患者血糖水平升高的频率高于普通人群。
